Poly Medicure Ltd.
POLYMED · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,237.26.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%10.8%
- ✓Low debt (D/E < 0.5)0.11x
- ✕Positive free cash flow
- ✓Revenue growth > 10%21%
- ✕Earnings growing-27%
- ✓Net margin ≥ 10%17.2%
- ✓Current ratio > 1.53.37
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 13.22
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (17.2%).
- •Financially solid — Altman Z 13.22.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (2/9).
Opportunities
- •Revenue growing (21% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Poly Medicure Ltd.
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid line
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.